Skip to main content

Table 1 Patient characteristics

From: Accuracy evaluation of mainstream and sidestream end-tidal carbon dioxide monitoring during noninvasive ventilation: a randomized crossover trial (MASCAT-NIV trial)

  Included patients
N = 60
Age, mean (SD), years 70.7 (11.2)
Male, n (%) 37 (61.7)
Body mass index, mean (SD), kg/m2 24.9 (4.0)
Patient category  
 Non-scheduled surgery, n (%) 16 (26.7)
 Scheduled surgery, n (%) 23 (38.3)
 Medical, n (%) 21 (35.0)
APACHE II score, median (IQR), points* 19 (14–25)
SOFA score, median (IQR), points* 8 (7–11.5)
Updated Charlson comorbidity index, median (IQR), points 3 (2–4)
 Chronic heart failure, n (%) 40 (66.7)
 Chronic respiratory failure, n (%) 8 (1.3)
 Renal disease, n (%) 35 (58.3)
Mechanical ventilation duration, days† 2 (2–4)
Weaning category  
 Short weaning, n (%) 50 (83.3)
 Difficult weaning, n (%) 10 (16.7)
 Prolonged weaning, n (%) 0 (0)
Glasgow Coma Scale, median (IQR), points† 14 (13–15)
Vasoactive drugs use, n (%) 32 (53.3)
Nasal gastric tube placement, n (%) 40 (66.7)
Reintubation within ICU stay, n (%) 3 (5.0)
Length of ICU stay, days 4 (3–8)
Length of hospitalization§, days 33 (23.5–41)
ICU mortality, n (%) 0 (0)
Hospital mortality, n (%) 10 (16.7)
  1. APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, Intensive Care Unit; SOFA, Sequential Organ Failure Assessment
  2. *At ICU admission
  3. At the day of extubation
  4. Defined by the WIND criteria
  5. §Excluded 10 patients who died